Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ATIS is on the move! -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (1865)	7/27/1999 11:20:00 PM
From: Marshall Teitelbaum	Read Replies (1) \| Respond to of 2205

Rick, Sure has been dead around here lately. The Inamed conference call was very positive toward ATIS, and the last few days have finally seen some upward movement of ATIS, albeit not on huge volume. Could involve S&N's move with another company they had a good sized stake in, or could be many other things. Looked like on Thompson today that there were 100,000 institutional shares purchased today in 2 50,000 share deals. Coming to a fork in the road here technically, as 3.56 is where S&N recently put their 10 million....so this is obviously a point of resistance. I would expect bigger volume if this is truly a sign of things to come with any noted fundamental progress. The questions now are still open to all as to the timing of the study(is sept/oct submission to the fda still likely, etc?). Anyway, for what it's worth, Inamed spoke of 5 licensed ATIS products that they feel have big potential, with a 3-5 year timeframe. They gave one example of using human collagen for lumpectomies to avoid dimpling with breast reconstruction(over 300,000 done per year in the usa). Okay, done with the typing for the moment. Anyone else still out there? Regards, Marshall

To: Rick Strange who wrote (1865)	8/5/1999 11:15:00 PM
From: Marshall Teitelbaum	Read Replies (1) \| Respond to of 2205

Rick, Missing in the current environment is the extremely important long-term fundamental fact that optimization of the cartilage product is apparently complete.......meaning that the clinical trial should start as originally hoped in the 1Q, 2000, without the retrospective analysis possibility that DG went through. Of course ATIS won't have much to say regarding DG at this point, as would be expected, and they are still in a quiet period so can't really say anything anyway. Sounds as if they're still sticking with the thought of being on track to submit to the FDA in the 4Q if statistical analysis for the interim trial is significant. Regards, Marshall